摘要
应用银染法测定６３例原发性骨肿瘤（恶性２８例，良性２０例，ＧＣＴ１５例）Ａｇ－ＮＯＲ，结果显示：恶性骨肿瘤Ａｇ－ＮＯＲ计数（８．６１±２．３３／核）明显高于良性骨肿瘤（１．２５±０．２０／核），两者有高度显著性差异（Ｐ值＜０．０１）；两组不同预后的恶性骨肿瘤Ａｇ－ＮＯＲ亦有显著性差异（Ｐ值＜０．０１）；ＧＣＴ与恶性骨肿瘤，及不同Ｊａｆｆｅ分级的两组ＧＣＴ之Ａｇ－ＮＯＲ均无显著性差异（Ｐ值＞０．０５），但ＧＣＴ与良性骨肿瘤之Ａｇ－ＮＯＲ有显著性差异（Ｐ值＜０．０１）．本研究提示：（１）Ａｇ－ＮＯＲ是原发性骨肿瘤良恶性鉴别的一项可靠指标；（２）Ａｇ－ＮＯＲ检测有助于对恶性骨肿瘤的预后估计；（３）对所有ＧＣＴ均应考虑恶性的可能，Ｊａｆｆｅ分级不宜作为反映ＧＣＴ生物学行为的标准．
Sixty-threespecimensinparaffinembeddedsectionsofprimarybonetumorswerestud-iedwithsilverstainingtechnique(Ag-NOR)andtheresultswereevaluatedforthediferentiationbenig-nancyfrommalignancyandtheassessmentoftheprognosis.Itwasrevealedthatmalignantbonetumorscelspossessedmorethan6Ag-NOR(8.61±2.33/nuclei)andbenignbonetumorscelslessthan3Ag-NOR(1.25±0.20/nuclei).AsignificantdiferenceinthenumberofAg-NORbetweenmalignantcelsandbenigncelswasobserved(P<0.01).ThedataofAg-NORshowednosignificantdiferencebe-tweenthegiantceltumorsofboneandmalignantbonetumors(P>0.05).ApparentlyAg-NORcountisadependableparameterforthediferentiationofbenignancyfrommalignancy.anditisusefulfortheassessmentoftheprognosisofbonetumors.Differencedoesnotexistinbetweenthegiantceltumorsofboneandthemalignantbonetumors.Theauthorsconsidergiantceltumorsofboneasmalignantbonetumors.TheJafe'smethodofgradingseemsunsuitabletodescribethebiologicbehaviorofgiantceltumorsofbone.
出处
《中华骨科杂志》
CAS
CSCD
北大核心
1996年第11期699-702,共4页
Chinese Journal of Orthopaedics
